Small-molecule anti-COVID-19 drugs and a focus on China's homegrown mindeudesivir (VV116).
10.1007/s11684-023-1037-3
- Author:
Qiuyu CAO
1
;
Yi DING
1
;
Yu XU
1
;
Mian LI
1
;
Ruizhi ZHENG
1
;
Zhujun CAO
2
;
Weiqing WANG
1
;
Yufang BI
1
;
Guang NING
1
;
Yiping XU
3
;
Ren ZHAO
4
Author Information
1. Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
2. Department of Infectious Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
3. Clinical Trials Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. xyp30363@rjh.com.cn.
4. Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. zhaorensurgeon@aliyun.com.
- Publication Type:Review
- Keywords:
COVID-19;
antiviral drugs;
mindeudesivir
- MeSH:
Humans;
Ritonavir/therapeutic use*;
COVID-19;
Antiviral Agents/therapeutic use*;
China;
Nitriles;
Lactams;
Proline;
Adenosine/analogs & derivatives*;
Leucine
- From:
Frontiers of Medicine
2023;17(6):1068-1079
- CountryChina
- Language:English
-
Abstract:
The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous efforts to develop therapeutic agents that target severe acute respiratory syndrome coronavirus 2 to control viral infection. So far, a few small-molecule antiviral drugs, including nirmatrelvir-ritonavir (Paxlovid), remdesivir, and molnupiravir have been marketed for the treatment of COVID-19. Nirmatrelvir-ritonavir has been recommended by the World Health Organization as an early treatment for outpatients with mild-to-moderate COVID-19. However, the existing treatment options have limitations, and effective treatment strategies that are cost-effective and convenient for tackling COVID-19 are still needed. To date, four domestically developed oral anti-COVID-19 drugs have been granted conditional market approval in China. These drugs include azvudine, simnotrelvir-ritonavir (Xiannuoxin), leritrelvir, and mindeudesivir (VV116). Preclinical and clinical studies have explored the efficacy and tolerability of mindeudesivir and supported its early use in mild-to-moderate COVID-19 cases at high risk for progression. In this review, we discuss the most recent findings regarding the pharmacological mechanism and therapeutic effects focusing on mindeudesivir and other small-molecule antiviral agents for COVID-19. These findings will expand our understanding and highlight the potential widespread application of China's homegrown anti-COVID-19 drugs.
